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Abstract
Background: Heart and coronary calcifications in hemodialysis patients are of very common occurrence and linked to 
cardiovascular events and mortality. Several studies have been published with similar results. Most of them were 
mainly cross-sectional and some of the prospective protocols were aimed to evaluate the results of the control of 
altered biochemical parameters of mineral disturbances with special regard to serum calcium, phosphate and CaxP 
with the use of calcium containing and calcium free phosphate chelating agents. The aim of the present study was to 
evaluate in hemodialysis patients classic and some non classic risk factors as predictors of calcification changes after 
one year and to evaluate the impact of progression on survival.
Methods: 81 patients on hemodialysis were studied, with a wide age range and HD vintage. Several classic parameters 
and some less classic risk factors were studied like fetuin-A, CRP, 25-OHD and leptin. Calcifications, as Agatston scores, 
were evaluated with Multislice CT basally and after 12-18 months.
Results: Coronary artery calcifications were observed in 71 of 81 patients. Non parametric correlations between 
Agatston scores and Age, HD Age, PTH and CRP were significant. Delta increments of Agatston scores correlated also 
with serum calcium, CaxP, Fetuin-A, triglycerides and serum albumin. Logistic regression analysis showed Age, PTH and 
serum calcium as important predictors of Delta Agatston scores. LN transformation of the not normally distributed 
variables restricted the significant correlations to Age, BMI and CRP. Considering the Delta Agatston scores as 
dependent, significant predictors were Age, PTH and HDL. A strong association was found between basal calcification 
scores and Delta increment at one year. By logistic analysis, the one year increments in Agatston scores were found to 
be predictors of mortality. Diabetic and hypertensive patients have significantly higher Delta scores.
Conclusions: Progression of calcification is of common occurrence, with special regard to elevated basal scores, and is 
predictive of survival. Higher predictive value of survival is linked to the one year increment of calcification scores. 
Some classic and non classic risk factors play an important role in progression. Some of them could be controlled with 
appropriate management with possible improvement of mortality.
Background
Coronary calcifications are of frequent occurrence in
chronic renal failure both in the conservative [1,2] and
hemodialysis stages [3]. They are considered to be
responsible for increased cardiac events and mortality
[4], since the extent of coronary calcium deposits are
associated with decreased survival [5]. Calcifications are
of two types, affecting media and intima. Medial artery
calcifications are known to be more frequently found in
diabetes mellitus and uremia. Intimal calcifications are
located in the atherosclerotic plaques and denote the
presence of atherosclerotic changes of the arteries [6].
However, with the currently available non invasive
means, either Electron Beam or Multislice Computerized
Tomography, there is no possibility to distinguish
between intimal and medial calcifications. Most of the
clinical studies of uremic vascular calcifications, mainly
devoted to frequency of occurrence and to risk factors
enhancing calcium deposits [7-10], were based on cross-
sectional data. It has been found by several authors that
most of patients on hemodialysis, about 80%, are affected
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by coronary calcifications while only 20% or less are unaf-
fected [3,8]. Patients showing unaffected arteries remain
generally free of calcium deposits when followed for long
periods of time. These patients are probably protected
from calcifications thanks to inhibitory factors which
have been in part identified [11,12]. Above all, age and
HD age are important risk factors, together with serum
phosphate, serum calcium and CaxP product. Also PTH
has been considered in many studies as a risk factor of
coronary calcification [13] and mortality [14-16], with
special regard to cases of severe hyperparathyroidism. As
previously stated, most of the studies to identify risk fac-
tors published to date are of a cross-sectional type, not
statistically strong enough to show a cause-effect rela-
tionship, while only a few were prospective [17-20]. In
three of them mere progression of calcification scores
was evaluated [17,19,20], while in another [18] the study
was conducted to evaluate the effect on progression of
phosphate chelating drugs. In the present study hemodi-
a l y s i s  p a t i e n t s  h a v e  b e e n  e v a l u a t e d  b y  M u l t i s l i c e  C T
basally and after 12-18 months. The relationship between
clinical data, basal humoral values and calcification
scores, and progression of heart calcifications and mor-
tality were evaluated in order to establish relevant risk
factors and their linkage to fatal events.
Methods
Eighty-one unselected patients with end-stage renal dis-
ease on hemodialysis were studied to evaluate the evolu-
tion of coronary and heart calcification scores. This
study, due to its observational nature, has not required
ethical approval. Samples were collected as part of the
standard care. The patients had a mean age of 59.2 ± 10.4
years and hemodialysis vintage of 82.5 ± 99.5 months. Sex
distribution was 54 M/27 F. 8 patients had diabetes melli-
tus and 38 patients were affected by arterial hypertension.
Causes of renal failure were: chronic glomerulonephritis
in 19 patients; hypertension/ischemic nephropathy in 25
patients; polycystic kidney disease in 7 patients; diabetic
nephropathy in 6 patients; renal malformations in 2
patients; and unknown in 22 patients. Exclusion criteria
included ethanol or drug abuse, malignancy, clinical car-
diovascular disease, chronic inflammatory disease,
human immunodeficiency virus infection, use of steroids,
antiepileptic drugs, non-steroidal anti-inflammatory
drugs, estrogens and anticoagulants. All patients were
treated with hemodialysis. Hemodialysis was based on
standard bicarbonate dialysis using Cuprophan or Low-
Flux-PolySulfone (LF-PS) membranes, 20% with acetate-
free biofiltration (AFB) using Polyacrylonitrile-.AN69
(PAN-AN69 ST), or with hemodiafiltration using Helix-
one (FX80) or Polycarbonate (Spiraflo SG 8 Plus). The
dialysis sessions lasted 4 hours and were delivered at con-
stant blood and dialysate flow rate values of 300 and 500
ml/min, respectively. Calcium concentration in the
dialysate was 1.25, or 1.5 or 1.75 mmol/L (only 3 pts).
Most patients had been treated with relatively limited
doses of calcitriol administered orally (1,5 μg/wk) or
intravenously (calcitriol 4,5 μg/wk), but had discontinued
this treatment at the time of the study. However, 17
patients were on IV calcitriol treatment with weekly
doses ranging from 3 to 6 μg and 8 patients were treated
with paricalcitol, 10-16 μg per week. Calcitriol/Paricalci-
tol doses were adjusted to comply with KDIGO guide-
lines. 81% of the patients were on phosphate binders,
mainly calcium salts (calcium carbonate 1,9 ± 0,8 g/day)
and sevelamer (6200 ± 2010 mg/day). In the majority of
patients, regular intravenous erythropoietin treatment
was underway.
Blood samples for biochemical evaluations were drawn
prior to a dialysis session. Serum samples were stored at -
30°C until the assays. The following assays were made:
serum calcium, phosphorus, alkaline phosphatase, intact
PTH, serum albumin, cholesterol, triglycerides, Fetuin-A,
CRP, 25-OHD and Leptin.
Serum calcium, phosphorus, alkaline phoshatase and
other biochemical parameters were measured by colori-
metric methods using a Roche autoanalyzer or other
standard laboratory techniques. Total calcium was cor-
rected for serum albumin using the equation: Calcium =
Ca + 0.8 (4.0 - albumin, g/dl). Normal values of these
variables are reported in Table 1. Serum intact PTH was
measured by an IRMA (Nichols Institute Diagnostic, San
Juan Capistrano, CA). Both 1-84 and "7-84" PTH species
are measured together. The normal range of values is 10
to 65 pg/ml. Fetuin-A was measured with an ELISA kit
(Epitope Diagnostics Inc., San Diego). Leptin concentra-
tions were determined with a radioimmunoassay for
human leptin (Mediagnost, Reutlingen, Germany), which
uses a high affinity polyclonal antibody specific for this
protein. Serum 25-hydroxycholecalciferol was measured
with a radioimmunoassay provided by IDS (Boldon, UK),
following an extraction procedure with acetonitrile. The
assay measures both 25-OHD3 and 25-OHD2.
Multislice computed tomography (MSCT) was per-
formed basally and after 12-18 months, with a 64-channel
multidetector scanner (LightSpeed VCT, General Electric
Medical Systems, USA). A retrospective gating technique
was used to synchronize the data reconstruction with the
ECG signal. Mean heart rate during MSCT was 70 ± 8
beats/min (range 50 to 85). All scans were performed
with the following parameters: detector collimation 64 ×
2.5, reconstruction interval 160 mm, gantry rotation time
0.35 s, tube voltage 120 Kv, tube current 300 mAs effec-
tive, field of view (FOV) 25 cm, medium smooth convolu-
tion filter, acquisition volume 12 cm (i.e. pulmonary
artery bifurcation to diaphragm), cranio-caudal scan
direction. Images were obtained during a single breath-Coen et al. BMC Nephrology 2010, 11:10
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Table 1: Baseline Clinical, Biochemical Data, Calcification Scores and Normal Values
Parameter Mean Median SD Interquartile 
range
Normal value
Number 81
Gender (M/F) 54/27
Age, years 58,7 10,8
HD Age, months 45 99,5
BMI 23,4 4 18-24*
Calcium, mg/dl 9,3 1 8,5-9,5
Phosphate, mg/dl 5,4 1,4 3,5-5,5
Albumin, g/dl 3,9 0,4 3,5-5,2
Ca, corrected, mg/dl 9,3 1,1 8,5-9,5
PTH, pg/ml 300 399,9 10-65
Cholesterol, mg/dl 149 41,2 150-210
HDL, mg/dl 43 14 35-65
Cholesterol/HDL 103,6 45,6 3,1-4,7
LDL, mg/dl 82,6 32,4 60-150
Triglicerides, mg/dl 140 142 50-180
HB, g/dl 11,7 1,2 13,5-15
Kt/V 1,3 0,3 ≥1,2
Fetuin-A, g/L 0,5 0,2 0,5 - 1,5
CRP, mg/dl 1 4,2 0 - 3
Alkaline Phosphatase, U/L 149 117,3 35 - 125
25 OHD, ng/ml 19,3 9 20-40
Leptin, ng/ml 6,7 8,7 2,5-15Coen et al. BMC Nephrology 2010, 11:10
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hold of approximately 5 to 7 seconds. Image reconstruc-
tion was performed using three windows at 70, 75 and
80% of the time between two consecutive R-R intervals,
which corresponded to the end-diastolic phase of the car-
diac cycle. The phases with minimal motion were
selected and used for calculating Calcium scoring.
All MSCT data were transferred to a GE AW Worksta-
tion (software version 4.2, General Electric Medical Sys-
tems, USA) for post-processing. Calcium scoring was
performed on the reconstructed image sets with com-
mercially available software (SmartScore™ 4.0, General
Electric Medical Systems, USA) [21]. Calcium was scored
according to the Agatston method to quantify the
amount of calcification in the coronary arteries. A focus
of coronary calcium was defined as the presence of four
or more contiguous pixels with more than 130 Hounsfield
units. The total calcium score was calculated from the
sum of the individual scores of the four major epicardial
coronary arteries. Informed consent was obtained from
all patients.
The statistical evaluation was carried out using a per-
sonal computer equipped with a statistical package (SPSS
for windows, Chicago, Illinois, release 13.0). In addition
to descriptive statistics for the selected variables, Kolm-
ogorov-Smirnov test was employed for the continuous
variables to compare the observed cumulative distribu-
tion function with the normal distribution. Non paramet-
ric (Spearman) correlations were evaluated. Agatston
score was measured basally and after 12-18 months. All
values were normalized to 365 days, assuming a linear
trend of calcification over time. The patient's survival was
followed for additional 2 years. The increment in Agat-
ston score observed between baseline and one year was
called delta. Logistic models, using tertiles of the depen-
dent variables (coronary Agatston score), were performed
to examine the relationship between the coronary cal-
cium scores (baseline and delta) and clinical and bio-
chemical parameters. In the logistic regression models,
only those independent variables that showed to have sta-
tistically significant Spearman correlation with the
dependent variable were included. Although statistically
associated in bivariate analysis, some variables were
excluded by logistic models because of collinearity prob-
lems. Cox regression analysis, stepwise method, has been
used to investigate the association between Agatston
score and mortality. The Cox regression was adjusted for
age, gender, HD age, calcium and PTH. In case of OR well
below unity, we used a scientific notation, reporting only
the exponent (E) of base 10. A p-value < 0,05 was consid-
ered statistically significant.
Results
Clinical characteristics, serum biochemistry and calcifi-
cation scores of the patients are reported in Table 1. In
case of normally distributed variables, mean and standard
deviation were shown, otherwise median and inter-
quartile range were reported. Coronary calcifications
were found in 71 of 81 patients. In table 2, left side, the
non parametric correlations between the basal calcifica-
tion scores and the basal clinical and humoral parameters
are reported. Several parameters are found to be signifi-
cantly correlated to the basal scores, like Age, HD Age,
PTH and CRP. On the right side of Table 2, the logistic
regression's output adjusted for gender is reported, con-
sidering the tertiles of basal Agatston scores as dependent
variables. The OR is referred to the high tertile compared
to the low tertile as reference category. Cut-off values of
Agatston score tertiles are: basal score, 157,6 and 1273;
delta score, 12,2 and 239. Age (p = 0,001) and HD Age (p
= 0,013) are found to be significant predictors of the basal
Agatston scores. Which variables have been found to pre-
dict the value of the scores after one year? Firstly, we
Therapy: Calcium carbonate or 
Sevelamer
81,4%
Hypertension, yes 47,4%
SIST, mmHg 122,4 19,2
DIAST, mmHg 71,2 11,1
Coronary Agatston Score t 0 481 1782,5
Coronary Agatston Score t1 528,2 2405,9
T0, baseline scores; T1, one year scores
* Non CKD normal values
Table 1: Baseline Clinical, Biochemical Data, Calcification Scores and Normal Values (Continued)Coen et al. BMC Nephrology 2010, 11:10
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observed a strong association between basal calcification
scores values and the delta increment after one year (p =
0,001): a low basal score is associated with a low delta,
while high basal score with a high increment. Then, the
answer to the question is reported in Table 3 and 4, where
correlations between basal values of parameters and delta
scores are reported (left sides). The logistic regressions
presented in those tables have been adjusted for HD age
and gender. As shown in Table 3, age (p = 0.042), calcium
(p = 0.047) and PTH (p = 0.027) are significant predictors
in calculating the risk of increased Agatston score after
one year, while Fetuin (p = 0,027) is a protective factor. In
Table 4 the results of a logistic regression of three catego-
rized delta Agatston score as dependent variable are
reported: no delta coronary calcification (reference cate-
gory), those with a medium increment (delta <1000) and
those with severe (delta >1000) coronary calcification
increment. In the model we considered as independent
variables only those that resulted as statistically associ-
ated in logistic regression of table 3. Calcium (p = 0,036)
is a risk factor in moderate delta increment of Agatston
score, but for severe calcification other variables are sta-
tistically significant: age (p = 0,036), PTH (p = 0,030) and,
as protective factor, Fetuin-A (p = 0,023).
Table 3: Non parametric significant correlations and logistics regressions, adjusted for gender and HD age, of delta 
Agatston scores
Bivariate analysis Logistic Regression
Variables Spearman p-value OR* C.I. 95% p-value
Age 0,401 0,001 1,198 1,006 - 1,426 0,042
BMI 0,390 0,001 1,375 - 0,106
Calcium 0,360 0,001 4,554 1,018 - 20,384 0,047
Ca corrected 0,362 0,001 - - NC
PTH 0,384 0,001 1,007 1,001 - 1,013 0,027
Fetuin-A -0,345 0,012 5,84 E-07** 4,6 E-12** - 0,074 0,017
CRP 0,321 0,020 0,890 - 0,139
* in logistic regression dependent variables are tertiles of Delta Agatston Score: increment more than 239 versus increment up to 12 (reference 
category). Pseudo R square (Cox and Snell) = 0,505
**scientific notation
Table 2: Non parametric significant correlations and logistics regressions, adjusted for gender, of basal Agatston score
Bivariate analysis Logistic Regression
Variables Spearman p-value OR* C.I. 95% p-value
Age 0,358 0,001 1,136 1,056 - 1,223 0,001
HD Age 0,228 0,039 1,012 1,002 - 1,021 0,013
PTH 0,263 0,017 1,002 - 0,069
CRP 0,326 0,018 1,400 - 0,106
* in logistic regression dependent variables are tertiles of basal Agatston score: high versus low (reference category). Pseudo R square (Cox and 
Snell) = 0,330Coen et al. BMC Nephrology 2010, 11:10
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In Figure 1, a chart showing the surviving patients,
stratified by tertiles of delta Agatston after one year is
shown. There were 11 death among the patients, 5 due to
cardiovascular events. 72.7% of the deaths were observed
among those who showed a worsening of calcifications
after one year. A Cox regression, stepwise method, has
been carried out to evaluate the risk factors of mortality.
Age, gender, HD age, PTH, calcium and Agatston score
were considered as covariates. A statistically significant
cumulative mortality hazard ratio for Agatston Score (p =
0,027) was found.
We have also performed parametric analysis and used
statistical models, carried out using the transformation in
LN for those variables not normally distributed. The
results were similar to those of non-parametric analysis
(not reported in the text).
D i a b e t i c  p a t i e n t s  h a v e  h i g h e r  l e v e l s  A g a t s t o n  s c o r e s
after one year (p < 0.042), even if they do not differ from
non diabetic patients in basal conditions. The same con-
clusions could be drawn for arterial hypertension. Delta
Agatston score was significantly higher in hypertensive (p
< 0.020) compared to non hypertensive HD patients
Discussion
In the last 10 years intense scientific interest has been
dedicated to the increased cardiovascular and all-cause
mortality of patients with CKD, both on predialysis and
dialysis stage [4]. It is known that most of the patients
with renal insufficiency, at whatever stage, die mainly due
to heart disease well before reaching the stage of hemodi-
alysis [22]. There is an accelerated atherosclerosis in ure-
mia [23] which is partly associated to calcification of the
arteries, both in the intima and in the media. Calcifica-
tion of the media is prevailing in uremia, as it is with dia-
betic patients. Calcification of arteries, with special
regard to coronary arteries can be detected by radiologi-
cal techniques, which however cannot distinguish
between intimal and media calcifications. However, vas-
cular calcification is very frequent in uremia and has a
recognized association with worse survival prognosis [5].
In vivo studies have shown hyperphosphatemia to be an
important risk factor of death [24], and in vitro observa-
tions have shown that increased phosphate concentra-
tions are an important factor in the calcification of the
smooth muscle cells of the media, which can be able to
induce differentiation of these cells in osteoblast-like cells
and to induce osteogenetic changes of arterial wall and
calcification [25]. Many studies have evaluated the impact
of appropriate phosphate control with chelating agents
on the process of vascular calcification in hemodialysis
patients and compared calcium containing chelating
drugs to calcium-free drugs [18,26,27], like sevelamer and
lanthanum carbonate. These studies have been con-
ducted prospectively showing that calcium-free chelating
Table 4: Logistics regressions, adjusted for gender and HD age, of categorized delta Agatston scores
Logistic Regression
Variables OR C.I. 95% p-value
delta increment < 1000 Age 1,044 - 0,363
Calcium 3,716 1,089 - 12,678 0,036
PTH 1,003 - 0,132
Fetuin-A 0,015 - 0,059
delta increment > 1000 Age 1,178 1,010 - 1,373 0,036
Calcium 1,550 - 0,584
PTH 1,005 1,001 - 1,010 0,030
Fetuin-A 0,001 4,1 E-07** - 0,336 0,023
Reference category: delta increment equal to zero
Pseudo R square (Cox and Snell) = 0,499
**scientific notationCoen et al. BMC Nephrology 2010, 11:10
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agents induce a lower increase of vascular calcification
with time, compared to calcium containing chelating
drugs [18]. Other studies have been planned and pub-
lished to evaluate which are the major risk factors of vas-
cular calcifications, mainly with cross-sectional protocols
[9,10,28-30]. In addition to classical risk factors linked to
deranged mineral metabolism, other non classical factors
of vascular calcification and mortality have been identi-
fied, like Fetuin-A, Osteoprotegerin and FGF 23
[10,11,29]. Only a few studies have been conducted pro-
spectively to evaluate progression of calcification in HD
patients [17,19,20]. This study, made on a cohort of 81
hemodialysis patients, is a statistically more significant
prospective analysis of the evolution of calcium deposits.
The study strengthens the importance of several classical
risk factors considered markers of mineral metabolism
derangements, like serum calcium and PTH, and also
Age, HD vintage and CRP. In addition, the study under-
lines the protective effect of Fetuin-A. Serum phosphate
did not reach a statistically significant level, probably due
to a limited range of values. In the evaluation of predic-
tors of calcification progression, Age, serum calcium,
PTH and Fetuin-A were selected as significant variables.
The importance of PTH as a risk factor of vascular calcifi-
cation is in apparent contrast with the histological find-
ings of London et al [30], but in line with translational
studies [31-33] and a clinical contribution [13]. In addi-
tion, the study highlights the increased mortality in the
patients with higher calcification score progression and
also validates earlier findings of a higher risk of progres-
sion in the patients with higher basal calcification scores
[20]. Our results show that a higher increase of calcifica-
tion after one year is associated to increased mortality.
Monitoring progression of calcifications is of value in the
survival evaluation of patients.
This study, in spite of the longitudinal approach, has
some limitations mainly due to the relatively limited
number of patients in the tertile groups. In addition the
assumption was made that the progression of calcifica-
tion deposits in the arteries was linear with time in the
assessment of coronary calcium increment after one year.
We used a retrospective gating in the evaluation of the
score, due to frequent heart rhythm disorders in our
patients, preventing the use of beta-blockers.
Conclusions
This study of 81 hemodialysis patients examines which
factors are predictive of basal coronary calcification and
of their progression. Age and HD vintage, PTH and CRP
are significant factors of coronary calcifications on the
bivariate analysis while regression analysis selected Age
and HD age. The increment of calcifications after one
year was predicted by Age, serum Calcium, PTH and
Fetuin-A. Categorized delta Agatston scores selected
Age, serum Calcium, PTH and Fetuin-A. The delta incre-
ment of coronary calcification was predictive of mortal-
ity. As a further deduction, there are factors of
progression which cannot at present be controlled, like
Age and Fetuin-A, and other risk factors which could be
brought into control with appropriate treatment with a
potential improvement of expected survival.
Figure 1 Tertiles of delta Agatston scores and survival.
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